Immunofluorescence lateral chromatog. (IFLC) is a quant. detection technique used to screen C-reactive protein and procalcitonin (PCT) monoclonal antibodies with high efficiency and specificity. This study investigated the application value of IFLC combined with the detection of hypersensitive C-reactive protein (hsCRP) and PCT in patients with mental diseases associated with COVID-19 infection. Sixty-four patients with mental disease admitted to our hospital from Jan. to Apr. 2020, were selected as research subjects. Based on the diagnostic criteria for COVID-19 in the "Corona Virus Disease 2019 Diagnosis and Treatment Scheme version 6, all patients were tested using the nucleic acid amplification test for COVID-19 and were divided into two groups of 6 infected and 58 non-infected patients. Subsequently, the patients' hsCRP and PCT levels were measured using IFLC and an automatic biochem. analyzer (BA). The results showed that the hsCRP and PCT levels in the infected group were higher than the non-infected group. Addnl., the anal. ultracentrifugation (AUC), sensitivity, and specificity of hsCRP were higher than PCT. The AUC, sensitivity, and specificity of hsCRP + PCT measured jointly were significantly higher than hsCRP and PCT measured sep. The BA results showed that the AUC, sensitivity, and specificity of hsCRP were higher than PCT. The AUC, sensitivity, and specificity of hsCRP + PCT measured jointly were significantly higher than hsCRP and PCT measured sep. Comprehensive anal. showed that the AUC, sensitivity, and specificity of hsCRP + PCT tested using IFLC were significantly higher than using the BA. All of the above differences were statistically significant (P < 0.05). It was concluded that the joint detection of hsCRP and PCT by IFLC helped identify and diagnose mental diseases associated with COVID-19 infection.